Chadi hosts Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, hematology consultant in the UK, for a broad discussion aimed to simplify an often complicated disease: Hodgkin lymphoma. The duo talk about early-stage disease categorizing, treatment considerations for each stage, reasonable clinical trial endpoints of practice-changing potential, adverse effects resulting from intensive treatments, notable clinical trials and novel treatment approaches, and programs for young adult survivors. This episode is a perfect refresher to get you in the spirit for the ASH Annual Meeting – just a few weeks away!
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
